This technology is a method to treat Alzheimer’s disease by reducing the level of the cellular biomarker APP-C99.
Currently, there is no cure for Alzheimer’s disease (AD) and few FDA-approved drugs available to alter disease progression. Since AD diagnosis involves obtaining a complete medical history often including expensive diagnostic scans, performing cognitive tests, and excluding other possible causes of dementia, there is already great potential for delays in treatment. Early diagnosis, effective tracking of disease progression, and finally, therapeutics to prevent and treat AD would lessen the burden of cognitive decline.
This technology reduces a patient’s level of endoplasmic reticulum-mitochondrial-associated membrane (ER-MAM) localized APP-C99 in cells using a variety of different pharmacological approaches, including but not limited to γ-secretase activators. Patients with Alzheimer’s disease have heightened levels of APP-C99, a byproduct of the pathway that drives the buildup of β-amyloid (Aβ). This technology aims to treat AD by reducing the function and concentration of APP-C99 in cells.
This technology has been validated with human patient cell lines.
Patent Pending (US20220395486)
Patent Pending (EP3702470)
Patent Issued (WO/2019/173795)
IR CU15147, 2312, 2312-a
Licensing Contact: Kristin Neuman